Meet Our TED Community Partners
TED COMMUNITY ORGANIZATION, a nonprofit 501(c)(3) dedicated to thyroid eye disease (TED), serves as a vital hub for advocacy, support, education, and research, ultimately contributing to improved outcomes and a better quality of life for individuals affected by TED. We greatly appreciate the support of our partners as they make our important and impactful work possible.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
![]()
argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. We bring our antibody engineering expertise to pioneering researchers with the intent to advance immunology breakthroughs into differentiated medicines for patients. Through collaboration, we have a common purpose and can accelerate discovery processes to bring solutions to patients who need them. argenx is currently working on a medication for thyroid eye disease (TED).
![]()
Viridian is a biopharmaceutical company focused on engineering and developing potential next-generation medicines for people living with autoimmune and rare diseases. Viridian is studying multiple potential new medicines in clinical studies for thyroid eye disease (TED) and advancing preclinical programs for other autoimmune conditions.
At Viridian, we are dedicated to creating solutions for people affected by autoimmune and rare diseases and have a team that is passionate and caring about this mission. We know that this work cannot be done in isolation and are committed to collaborating with the patient community to educate and raise awareness among all stakeholders, advance research, and establish impactful support initiatives to meet the unique needs of the communities we serve.
For more information, please visit www.viridiantherapeutics.com and follow Viridian on LinkedIn and X.
![]()
We are a biopharmaceutical gene therapy company developing life-changing gene therapies for conditions affecting millions of people around the world. Our mission is to make gene therapies accessible – not just for the few – but for the many.
![]()
Prevent Blindness, a US organization, was established in New York in 1908 to prevent blindness and preserve sight for all ages. Its mission centers on public education, promoting improved public health systems, and advocating for public policy focused on early detection and eye care access. It aims to enhance early identification and treatment of vision disorders.
To address the lack of a program supporting patients in vision health, Prevent Blindness developed the ASPECT Program– Advocacy, Support, Perspective, Empowerment, Communication, and Training– which aims to strengthen our patient empowerment efforts for vision into a coordinated program that engages the individual in a more comprehensive manner. The goal of the ASPECT Program is to empower individuals to be engaged in their eye health from every direction and in every way.
Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. In doing so, we seek to develop medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.
We are a nimble, driven and accomplished team of entrepreneurs, physicians, and industry experts with a mission to thoughtfully develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases.
Please visit – https://clinicaltrials.gov/study/NCT06088979 or https://lpcur.com/TEDCommunityOrganization for more information about our spiriTED clinical study.
![]()
We are a clinical-stage immunology company, dedicated to enabling normal lives for people with autoimmune diseases. As trailblazers in anti FcRn technology, we are developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.
Immunovant’s two investigational products, batoclimab and IMVT-1402, are novel, fully human, monoclonal antibodies that target FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. We believe that both product candidates have the potential to address a variety of IgG-mediated autoimmune diseases as subcutaneous injections with dosing that may be tailored, based on disease stage and severity.
![]()
Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. We celebrate our unique history as the pioneers of scientific breakthroughs that have an incredible track record of improving lives. And yet, our ambitions are bigger and bolder. Together, we are united in a bold quest to solve the world’s most complex health challenges and serve society.
![]()
Sling Therapeutics is a biopharmaceutical company focused on late-stage development for thyroid eye disease, aspiring to improve the lives of patients and their families. Our team, consisting of highly experienced executives, drug developers, and scientific advisors, works with urgency to develop additional therapies for patients while upholding the highest standards of quality.
![]()
Leapcure starts by partnering with patient advocacy to connect patients with clinical trials. With an inclusive and values-driven approach, they are committed to empowering the patient voice to enhance the patient experience in clinical research. The approach delivers win-win-win results for all stakeholders in medical research; sponsors, sites, and patients alike. Leapcure helps achieve global breakthroughs for all. Heartfelt thanks to Leapcure for hosting the platform for the TED Community Organization CONNECTED 2025 virtual global conference during TED Awareness Week, November 10-15, 2025.








